Price
No data yet.
Social Signal Score
Analyst Ratings
29 analystsRevenue
$180.29M+1907.04%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Charles K. Gayer
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 435
- Beta
- 0.51
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- -3.19
Financials
Revenue
$180.29M+1907.0%Net Income
$37.92MEBITDA
$49.96MFree Cash Flow
$32.75MEPS (diluted)
$0.14Shares Outstanding (diluted)
267.62M+262.8%Operating Expenses
$125.39MCash & Debt
$375.00MReturn of Capital
$0.00Revenue by Segment (annual)
$874.84MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $874.84M | $263.86M | $1.26 |
| 2024 | $450.71M | $-88.88M | $-0.43 |
| 2023 | $331.41M | $-226.54M | $-1.18 |
| 2022 | $270.83M | $-247.12M | $-1.33 |
| 2021 | $157.17M | $-184.06M | $-1.03 |
| 2020 | $17.81M | $-182.81M | $-1.09 |
| 2019 | $48.84M | $-108.90M | $-0.94 |
| 2018 | $20.65M | $-101.25M | $-0.98 |
| 2017 | $25.19M | $-65.78M | $-0.78 |
| 2016 | $26.35M | $-55.14M | $-0.75 |
| 2015 | $48.26M | $-43.02M | $-0.59 |
| 2014 | $13.61M | $-45.19M | $-0.68 |
| 2013 | $17.33M | $-30.11M | $-0.55 |
| 2012 | $26.29M | $-39.08M | $-0.79 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $1.85
- Implied price
- $11.08
- Return from $7.22
- 8.9% a year
To earn 15.0% a year on these assumptions you'd need to buy at $5.51 — -23.7% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 2 | 4 | 6 | 8 | 10 |
|---|---|---|---|---|---|
| -2.0% | -20.6% | -8.8% | -1.1% | 4.7% | 9.5% |
| 3.0% | -16.6% | -4.2% | 3.9% | 10.1% | 15.1% |
| 8.0% | -12.5% | 0.5% | 8.9% | 15.4% | 20.7% |
| 13.0% | -8.5% | 5.1% | 14.0% | 20.7% | 26.3% |
| 18.0% | -4.4% | 9.8% | 19.0% | 26.1% | 31.8% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
30-79.31%Social Signal Score
Mentions (17)
- Newsglobenewswire.com·9d ago·Negative
BioCryst Presents New Real-World Evidence Showing Reduced Angioedema-Related Medical Visits After Switching to ORLADEYO® (berotralstat) at ACAAI 2026 Annual Scientific Meeting — Two real-world studies demonstrate reductions in healthcare resource utilization in HAE patients who initiated or switched to ORLADEYO ® from another prophylactic therapy —
View source ↗ - Newszacks.com·12d ago·Neutral
4 Commercial-Stage Biotechs Poised for Sustained Revenue Growth TGTX, BCRX, INSM and MDGL are expanding product sales through rising demand, broader patient access and new market opportunities.
View source ↗ - Newsseekingalpha.com·18d ago·Positive
BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2026 Earnings Call Transcript BioCryst Pharmaceuticals, Inc. ( BCRX ) Q3 2026 Earnings Call November 4, 2026 8:30 AM EST Company Participants Nick Wilder - Manager of Investor Relations Charles Gayer - CEO, President & Director Babar Ghias - CFO & Head of Corporate Development Sandeep Menon - Chief Research & Development Officer Conference Call Participants Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division Laura Chico - Wedbush …
View source ↗ - Newsmarketbeat.com·18d ago·Negative
BioCryst Pharmaceuticals Q3 Earnings Call Highlights BioCryst Pharmaceuticals NASDAQ: BCRX reported third-quarter results marked by growth in ORLADEYO revenue, higher profitability and progress across its hereditary angioedema, or HAE, portfolio, while maintaining its full-year ORLADEYO revenue outlook following a specialty-pharmacy transition.
View source ↗ - Newszacks.com·23d ago·Neutral
Wall Street Analysts See a 137.91% Upside in BioCryst (BCRX): Can the Stock Really Move This High? The consensus price target hints at a 137.9% upside potential for BioCryst (BCRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
View source ↗ - Newsglobenewswire.com·32d ago·Neutral
BioCryst to Report Third Quarter 2026 Financial Results on November 4 RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2026 financial results on Wednesday, November 4, 2026.
View source ↗ - Newsglobenewswire.com·48d ago·Negative
…a more disciplined R&D model centered on external innovation— RESEARCH TRIANGLE PARK, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the formation of a Scientific Advisory Board (SAB) comprising seven accomplished scientific and industry leaders with deep expertise across rare disease research and drug development.
View source ↗ - Newsschaeffersresearch.com·62d ago·Neutral
Biopharma Stock With Layers of Technical Support in Place After its most recent pullback, biopharmaceutical stock BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) bounced off the $8 level and has now reclaimed the 320-day moving average -- both of which have been key lines of pressure and support.
View source ↗ - Newsmarketbeat.com·65d ago·Negative
BioCryst Eyes $1B Rare-Disease Future Through External Innovation BioCryst Pharmaceuticals NASDAQ: BCRX is shifting its strategy toward external innovation as it seeks to expand beyond its ORLADEYO hereditary angioedema, or HAE, franchise, newly appointed Chief Executive Officer Charlie Gayer said at a Morgan Stanley event.
View source ↗ - Newsseekingalpha.com·68d ago·Positive
BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·72d ago·Negative
BioCryst Pharmaceuticals: Why The Selloff Could Be An Opportunity BioCryst Pharmaceuticals, Inc.'s shares remain under pressure. At the same time, Orladeyo revenue increased 6.7% QoQ to $158.2 million in the second quarter. BioCryst's royalty financing obligations declined from $465.7 million at the end of Q4 2025 to $426.8 million at the end of June.
View source ↗ - Newsglobenewswire.com·82d ago·Neutral
BioCryst to Present at Upcoming Investor Conference RESEARCH TRIANGLE PARK, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Tuesday, September 15, 2026, at 9:15 a.m. ET.
View source ↗ - Newszacks.com·83d ago·Negative
Is BioCryst Pharmaceuticals (BCRX) Stock Outpacing Its Medical Peers This Year? Here is how BioCryst Pharmaceuticals (BCRX) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.
View source ↗ - Newszacks.com·86d ago·Neutral
Wall Street Analysts Think BioCryst (BCRX) Could Surge 108.21%: Read This Before Placing a Bet The average of price targets set by Wall Street analysts indicates a potential upside of 108.2% in BioCryst (BCRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
View source ↗ - Newscnbc.com·86d ago·Negative
BioCryst is profitable. Now it wants to buy more rare disease drugs BioCryst expects up to $645 million in 2026 sales from its HAE drug Orladeyo, giving it capital to pursue external deals. As large drugmakers prioritize multibillion dollar assets, small and midsize biotech companies are increasingly stepping in to develop and acquire rare disease drugs.
View source ↗ - Newszacks.com·103d ago·Neutral
Implied Volatility Surging for BioCryst Pharmaceuticals Stock Options Investors need to pay close attention to BCRX stock based on the movements in the options market lately.
View source ↗ - News247wallst.com·103d ago·Neutral
A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst? BioCryst Pharmaceuticals (NASDAQ:BCRX) closed at $9.84 on August 10, 2026, giving the Durham-based rare-disease specialist a market cap of roughly $2.5 billion.
View source ↗
Earnings
Thu, Feb 25(in 3 months)
Consensus estimate $0.11 per share
Typical surprise +52.4% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Nov 4$0.14 vs $0.09beat
- Wed, Aug 5$0.30 vs $0.15beat
- Wed, May 6$-2.98 vs $0.06miss
- Thu, Feb 26$1.12 vs $0.07beat
- Mon, Nov 3$0.06 vs $0.07miss
- Mon, Aug 4$0.02 vs $0.03miss
Estimates and results for BCRX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BCRX officers and directors.
- Bought
- —
- Sold
- $4.7m
0 trades
11 trades
- Mckee Amy Esold
- Barnes Alane Psold
- Heggie Theresasold
- Barnes Alane Psold
- Barnes Alane Psold
- Barnes Alane Psold
- Barnes Alane Psold
- Barnes Alane Psold
89 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Cisneroshouse · CA31 · disclosed Sep 7, 2026 (59d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Dec 15, 2025 (32d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Nov 11, 2023 (26d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Oct 15, 2023 (30d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
